Pfizer-BioNTech vaccine candidate, BNT162b2, was 90% effective in preventing infection during the phase 3 clinical trial, which enrolled 43,538 participants, with 30% in U.S. and 42% abroad
from Latest News https://ift.tt/3fh9TFZ
Thursday, 19 November 2020
How sophisticated mRNA vaccines from Pfizer, Moderna are and how they work?
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment